Potential first-in-class antibody targeting the IL 13 receptor in moderate-to-severe atopic dermatitis
Our portfolio is led by eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor that has the potential to improve upon current biologics used to treat allergic disease. We are also developing farudodstat, a potent oral inhibitor of the enzyme DHODH, as a potential first-in-class treatment for alopecia areata.
|Program||Target||Indication||Preclinical||Phase 1||Phase 2||Phase 3||Anticipated milestones|
|Phase 3 initiation in 2024
Phase 2b biomarker data 2H 2023
|Type 2-driven disease|
|Farudodstat||DHODH||Alopecia areata||Phase 2a interim topline data 1Q 2024|
We focus on atopic dermatitis, alopecia areata and Type 2-driven diseases.Atopic dermatitis
Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide. Up to one-third of adult atopic dermatitis patients are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.
ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1, with potential to be a first-in-class therapy for atopic dermatitis. ASLAN004 is currently undergoing a phase 1 study for the treatment of atopic dermatitis. The SAD portion of the study was completed in the second quarter of 2019. The MAD portion of the study is ongoing. Positive interim data was announced in March 2021, and top line data is expected in mid-2021.